

## Collaboration with and support by Orion Pharma marketing organisations to patient organisations in 2014

### By country, in alphabetical order

<b>Austria:</b> Orion Pharma (Austria) GmbH	No collaboration or support in 2014
<b>Benelux:</b> Orion Pharma BVBA/SPRL	No collaboration or support in 2014
<b>Denmark:</b> Orion Pharma A/S	No collaboration or support in 2014
<b>Czech Republic:</b> Orion Oyj, organizační složka	To: ČIPA (= Česká iniciativa pro astma, Czech initiative for asthma) <ul style="list-style-type: none"> <li>Partnering of web-pages <a href="http://www.cipa.ciz">www.cipa.ciz</a> and educative material for patients (EUR 5530)</li> </ul>
<b>Estonia:</b> Orion Pharma OÜ	To: Tallin PD patients society <ul style="list-style-type: none"> <li>Bus rental for travel to the PD Conference Tallinn-Tartu-Tallinn (EUR 240)</li> </ul>
<b>Finland:</b> Orion Corporation, Orion Pharma	<p>To: Suomen Parkinson-liitto r.y.</p> <ul style="list-style-type: none"> <li>Lecturer for training courses for healthcare professionals.</li> <li>Sponsorship of coffee breaks</li> <li>Advertisement in Parkinson-postia magazine</li> <li>Sponsorship for re-printing a Parkinson's guide for health center doctors</li> <li>Production collaboration for patient guides</li> <li>Non-medicinal product donations to lotteries</li> <li>30<sup>th</sup> Anniversary Symposium, exhibition</li> </ul> <p>To: Allergia- ja astmaliitto r.y.</p> <ul style="list-style-type: none"> <li>Booth at an educational event for professionals</li> </ul> <p>To: Suomen Sydänliitto r.y.</p> <ul style="list-style-type: none"> <li>Sponsorship for printing of 3 patient guides</li> <li>Educational event for healthcare professionals</li> <li>Educational event for professionals on Marevan treatment</li> <li>Advertisement in the Sydän magazine for cardiologists</li> </ul> <p>To: Iholiitto r.y.</p> <ul style="list-style-type: none"> <li>Brochures and non-medicinal product samples provided at seminars and events</li> <li>Sponsorship for 'Ikääntyvä iho', a guide for treating ageing skin, and 'Käsien ihottumat' and 'Atooppinen iho' guides</li> </ul> <p>To: Diabetesliitto r.y.</p> <ul style="list-style-type: none"> <li>Booth at the Diabetes Seminar for healthcare professionals</li> <li>Advertisements in the Diabetes magazine</li> <li>Banner advertisement on diabetes.fi website</li> </ul> <p>To: Epilepsialiitto r.y.</p> <ul style="list-style-type: none"> <li>Sponsorship of a patient guide on adult epilepsy</li> <li>'Golden Partnership' in 2014</li> </ul> <p>To: Suomen Nivelyhdistys r.y.</p> <ul style="list-style-type: none"> <li>Sponsoring membership 2014</li> </ul>

- To: Helsingin Allergia- ja Astmayhdistys r.y.
- Product information in 'Allergiaportaali', the organisation's web service dealing with allergies
- To: Suomen Kilpirauhasliitto r.y.
- Advertisements in the "Kilpi" magazine for members
- To: Suomen Dystoniayhdistys r.y.
- Advertisement in the organisation's member bulletin
- To: Sydän ja keuhkosiirroksaat SYKE r.y.
- Letter seals
- To: Psoriasisliitto r.y.
- Sponsoring membership 2014
- To: European Parkinson's Disease Association EPDA
- Monetary support (EUR 5 000)

<b>Germany:</b> Orion Pharma GmbH	To: Deutsche Parkinson Vereinigung, dPv (EUR 802,50) • Supporting Parkinson congress 12-13 September 2014 in Kassel
<b>Greece:</b> Orion Pharma Farmakeftiki MEPE	No collaboration or support in 2014
<b>Hungary:</b> Orion Pharma Kft.	No collaboration or support in 2014
<b>Ireland:</b> Orion Pharma (Ireland) Ltd.	To: Parkinson's Association of Ireland (EUR 1,500) • Sponsorship of one Patient Information Meetings
<b>Italy:</b> Orion Pharma S.r.l.	No collaboration or support in 2014
<b>Latvia:</b> Orion Pharma Latvia Representative Office	No collaboration or support in 2014
<b>Lithuania:</b> UAB Orion Pharma	To: Lithuanian Parkinson's disease association (290 EUR) • Lithuanian Parkinson's association event on 11 April 2014
<b>Norway:</b> Orion Pharma AS	No collaboration or support in 2014
<b>Poland:</b> Orion Pharma Poland Sp. z.o.o.	No collaboration or support in 2014
<b>Portugal:</b> Orionfin Unipessoal Lda	No collaboration or support in 2014
<b>Russia:</b> Orion Pharma	No collaboration or support in 2014
<b>Slovakia:</b> Orion Pharma d.o.o.	No collaboration or support in 2014
<b>Slovenia:</b> Orion Pharma d.o.o.	No collaboration or support in 2014
<b>Spain:</b> Orion Pharma	No collaboration or support in 2014

<b>Sweden:</b> Orion Pharma AB	To: Svensk Dystoniförening (EUR 7,609) Supporting the organization to educate health care representatives in using physiotherapy for patients with cervical dystonis. Stand, material, speakers
<b>Switzerland:</b> Orion Pharma AG	No collaboration or support in 2014
<b>Ukraine:</b> Orion Pharma Ukraine	No collaboration or support in 2013
<b>UK:</b> Orion Pharma (UK) Ltd.	<p>To: Primary Care Respiratory Society PCRS (EUR 54,000, GBP 45,000))</p> <ul style="list-style-type: none"> <li>• Gold corporate sponsor, involves providing a financial support donation that PCRS can choose to spend on projects determined internally. Involvement and exhibition at the PCRSUK Annual Meeting.</li> </ul> <p>To: Intensive Care Society ICS (EUR 6,000; GBP 5,000)</p> <ul style="list-style-type: none"> <li>• Corporate sponsor support for the key intensive care clinician group for the UK, involves providing a financial support donation that the ICS can choose to spend on projects determined internally.</li> </ul> <p>To: UKCPA (EUR 504; GBP 420)</p> <ul style="list-style-type: none"> <li>• Corporate sponsor support for the key intensive care clinician group for the UK. This involves a providing a financial support donation that the UKCPA can choose to spend on projects determined internally.</li> </ul> <p>To: BACCN (EUR 2,624; GBP 2,000)</p> <ul style="list-style-type: none"> <li>• Corporate sponsor support for the key intensive care clinician group for the UK, involves providing a financial support donation that the BACCN can choose to spend on projects determined internally.</li> </ul> <p>To: Vanguard Study (EUR 2,800, GBP 2,000)</p> <ul style="list-style-type: none"> <li>• Looking at the effectiveness of Respiratory Nurse Specialists and the knowledge that this group of nurses has. Also addressed patients experience of Respiratory nurse specialist.</li> <li>• Ongoing study and further literature and scoping groups to be held</li> <li>• To conduct a scoping exercise to identify and prioritise a potential set of key Respiratory Nurse Sensitive Outcome Indicators (NSOI)</li> <li>• To assess the current evidence for specialist NSOI</li> <li>• To conduct pilot testing of the respiratory NSOI set to establish feasibility, reliability and validity of the tool</li> </ul> <p>To: National Inhaler Group (start up in Qtr 4 2014 to run through 2015/16) (EUR 6,000; GBP 5,000)</p> <ul style="list-style-type: none"> <li>• Several Pharma companies are involved in provided Corporate Support of this National UK Inhaler Group project.</li> <li>• The group was established earlier in 2014 and has the support of the professional and patient respiratory community and is made</li> </ul>

---

up of representatives of the British Thoracic Society, Primary Care Respiratory Society UK, Asthma UK, British Lung Foundation, Association of Respiratory Nurse Specialists, Respiratory Education UK, Education for Health, UK Clinical Pharmacy Association Respiratory Group, Association for Respiratory Technology and Physiology, and the Royal Pharmaceutical Society.

- The key aim is to promote the correct use of inhaled therapies to improve the outcomes of patients with respiratory conditions. It is our vision that every patient is able to use their inhaler correctly and is taught and assessed as such, by an appropriately trained healthcare professional. We are keen that this is standardised across the UK, and documented in patient records and that healthcare professionals are held to account.
-